NEWTON, Mass.--(BUSINESS WIRE)--Clinical Data, Inc. (NASDAQ: CLDA) today announced that its PGxHealth™ division has entered into an agreement with Lab21, a leader in molecular diagnostic testing services in Europe. Under terms of this agreement, Lab21 will have exclusive rights in the U.K. and Ireland to market and sell Clinical Data’s FAMILION® test, a genetic test designed to identify mutations in people with inherited cardiac channelopathies such as Long QT Syndrome (LQTS) and Brugada Syndrome. In addition, the parties have agreed to consider other proprietary, molecular and pharmacogenomic tests developed and commercialized by PGxHealth for future launch in the U.K. and Ireland.
